INCY catalyst calendar

INCYTE CORP

Upcoming catalysts
46
Cash runway
Cash generating
Cash & investments
$3461M
Phase 3 programs
51

INCYTE CORP is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Services-Commercial Physical & Biological Research.

The next scheduled catalyst is A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants on October 15, 2026. There are 46 upcoming events on record.

INCYTE CORP generates cash from operations, so a burn-based runway figure does not apply.

Across 219 concluded trials, 65% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants Trial Milestone Phase 1
October 19, 2026 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants Trial Milestone Phase 1
October 19, 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Trial Milestone Phase 3
October 19, 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Trial Milestone Phase 3
October 27, 2026 est. Next quarterly earnings (projected) Earnings —
November 5, 2026 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Trial Milestone Phase 2
November 20, 2026 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma Trial Milestone Phase 2
December 9, 2026 Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa Trial Milestone Phase 1
December 26, 2026 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Trial Milestone Phase 3
January 1, 2027 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Trial Milestone Phase 1
January 4, 2027 A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease Trial Milestone Phase 1
January 6, 2027 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD Trial Milestone Phase 1/Phase 2
March 27, 2027 A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Trial Milestone Phase 1
March 30, 2027 A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis Trial Milestone Phase 1
March 31, 2027 A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment Trial Milestone Phase 1
April 13, 2027 A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment Trial Milestone Phase 1
April 27, 2027 A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Trial Milestone Phase 2
April 30, 2027 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo Trial Milestone Phase 3
April 30, 2027 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Trial Milestone Phase 1
June 1, 2027 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Trial Milestone Phase 2
July 27, 2027 Study of INCB123667 in Subjects With Advanced Solid Tumors Trial Milestone Phase 1
July 30, 2027 To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva Trial Milestone Phase 2
August 29, 2027 Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab Trial Milestone Phase 2
September 23, 2027 Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders Trial Milestone Phase 2
September 28, 2027 A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Trial Milestone Phase 3
September 30, 2027 An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Trial Milestone Phase 2
February 28, 2028 Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib Trial Milestone Phase 3
February 29, 2028 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Trial Milestone Phase 1
March 14, 2028 A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms Trial Milestone Phase 1
March 25, 2028 Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Trial Milestone Phase 2
May 31, 2028 A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy Trial Milestone Phase 3
June 5, 2028 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Trial Milestone Phase 3
August 18, 2028 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies Trial Milestone Phase 1
September 15, 2028 A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma Trial Milestone Phase 3
October 9, 2028 A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Trial Milestone Phase 1
October 29, 2028 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Trial Milestone Phase 1
November 15, 2028 Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Trial Milestone Phase 3
December 29, 2028 A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer Trial Milestone Phase 3
January 31, 2029 A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) Trial Milestone Phase 2
May 3, 2029 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
May 14, 2029 A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy Trial Milestone Phase 2
June 15, 2029 A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia Trial Milestone Phase 3
May 24, 2030 Study of INCA036978 in Participants With Myeloproliferative Neoplasms Trial Milestone Phase 1
January 17, 2031 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Trial Milestone Phase 3
February 25, 2031 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Trial Milestone Phase 2
May 1, 2032 Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 Trial Milestone Phase 3

Track INCY alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open INCY in the tracker

Recent history

DateEventTypePhase
October 9, 2026 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Trial Milestone Phase 3
October 9, 2026 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Trial Milestone Phase 3
September 30, 2026 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Trial Milestone Phase 2
September 28, 2026 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Trial Milestone Phase 2
September 8, 2026 A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants Trial Milestone Phase 1
September 1, 2026 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Trial Milestone Phase 3
August 31, 2026 8-K filed: Other event Filing —
August 7, 2026 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Trial Milestone Phase 3
July 29, 2026 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors Trial Milestone Phase 1/Phase 2
July 28, 2026 Quarterly results filed (8-K) Earnings —
July 6, 2026 8-K filed: Other event Filing —
June 22, 2026 8-K filed: Other event Filing —
June 8, 2026 8-K filed: Other event Filing —
May 29, 2026 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. Trial Milestone Phase 2
May 17, 2026 A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants Trial Milestone Phase 1
May 11, 2026 A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib Trial Milestone Phase 2
April 28, 2026 Quarterly results filed (8-K) Earnings —
March 30, 2026 8-K filed: Leadership change Corporate —
March 30, 2026 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Trial Milestone Phase 3
March 26, 2026 8-K filed: Leadership change Corporate —
March 17, 2026 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) Trial Milestone Phase 3
March 6, 2026 8-K filed: Other event Filing —
March 3, 2026 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Trial Milestone Phase 2
February 26, 2026 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Trial Milestone Phase 1
February 24, 2026 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Trial Milestone Phase 3
February 10, 2026 Quarterly results filed (8-K) Earnings —
December 24, 2025 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
December 12, 2025 8-K filed: Leadership change Corporate —
December 10, 2025 Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants Trial Milestone Phase 1
October 28, 2025 Quarterly results filed (8-K) Earnings —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.